0001567619-23-001929.txt : 20230206
0001567619-23-001929.hdr.sgml : 20230206
20230206164944
ACCESSION NUMBER: 0001567619-23-001929
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230202
FILED AS OF DATE: 20230206
DATE AS OF CHANGE: 20230206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Landau Jeffrey B
CENTRAL INDEX KEY: 0001918615
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 23591298
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD., SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2023-02-02
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001918615
Landau Jeffrey B
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Business Officer
Common Stock
2023-02-02
4
A
0
40000
0
A
70725
D
Common Stock
4500
I
Fidelity Traditional IRA
Common Stock
3180
I
Schwab ROTH IRA
Stock Option (Right to Buy)
2.59
2023-02-02
4
A
0
100000
0.00
A
2033-02-01
Common Stock
100000
100000
D
Performance Stock Units (PSUs)
2023-02-02
4
A
0
75000
0.00
A
Common Stock
75000
75000
D
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
Includes 56,274 RSUs.
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date.
Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
2023-02-06